Telomir Pharmaceuticals Inc. has announced new preclinical cellular research results supporting the epigenetic modulation mechanism of its lead investigational compound, Telomir-1, in the form of Telomir-Zn. The data show that Telomir-Zn induces a coordinated redistribution of metals within cells, increasing intracellular zinc and reducing labile ferrous iron in a dose-dependent manner, without compromising cell viability. These effects were detected within 30 minutes of exposure and sustained for two hours. The findings suggest that Telomir-Zn may address key upstream drivers of cancer and aging by reducing oxidative stress and stabilizing epigenetic and mitochondrial function. The company has initiated manuscript submissions to peer-reviewed journals based on completed studies, with additional data from ongoing research still being generated. Telomir Pharmaceuticals plans to submit an Investigational New Drug application in the first quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-005199), on February 05, 2026, and is solely responsible for the information contained therein.